MX2020014124A - Preparacion de aptameros. - Google Patents

Preparacion de aptameros.

Info

Publication number
MX2020014124A
MX2020014124A MX2020014124A MX2020014124A MX2020014124A MX 2020014124 A MX2020014124 A MX 2020014124A MX 2020014124 A MX2020014124 A MX 2020014124A MX 2020014124 A MX2020014124 A MX 2020014124A MX 2020014124 A MX2020014124 A MX 2020014124A
Authority
MX
Mexico
Prior art keywords
aptamer
preparation
aptamer preparation
fgf2
formulation
Prior art date
Application number
MX2020014124A
Other languages
English (en)
Inventor
Yoshikazu Nakamura
Kazumasa Akita
Yusuf Ali
Original Assignee
Ribomic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribomic Inc filed Critical Ribomic Inc
Publication of MX2020014124A publication Critical patent/MX2020014124A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Abstract

La presente invención proporciona una formulación de preparación capaz de mantener de manera estable la actividad de un aptámero, particularmente un aptámero para FGF2, durante un largo periodo, proporcionando así una preparación farmacéutica que contiene un aptámero, particularmente un aptámero de FGF2, como un ingrediente activo.
MX2020014124A 2018-06-29 2019-06-28 Preparacion de aptameros. MX2020014124A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018124390 2018-06-29
PCT/JP2019/025766 WO2020004607A1 (ja) 2018-06-29 2019-06-28 アプタマー製剤

Publications (1)

Publication Number Publication Date
MX2020014124A true MX2020014124A (es) 2021-05-31

Family

ID=68986754

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014124A MX2020014124A (es) 2018-06-29 2019-06-28 Preparacion de aptameros.

Country Status (13)

Country Link
US (1) US20210269802A1 (es)
EP (1) EP3815715A4 (es)
JP (1) JP7340264B2 (es)
KR (1) KR20210025083A (es)
CN (1) CN112384246A (es)
AU (1) AU2019292134A1 (es)
BR (1) BR112020026634A2 (es)
CA (1) CA3105002A1 (es)
IL (1) IL279595A (es)
MX (1) MX2020014124A (es)
SG (1) SG11202012933QA (es)
TW (1) TW202012625A (es)
WO (1) WO2020004607A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115175684A (zh) 2020-02-06 2022-10-11 力博美科股份有限公司 视网膜下高反射病灶或伴有视网膜下高反射病灶的视网膜疾病的治疗剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
CN101317820B (zh) * 2007-04-19 2012-02-29 中国人民解放军军事医学科学院毒物药物研究所 生物亲和性配体分子介导的靶向脂质体，其制 备及其应用
JP2011515685A (ja) * 2008-03-26 2011-05-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 基質結合ビーズを長期間保存する方法
US9052323B2 (en) * 2009-08-27 2015-06-09 The University Of Kansas Osmolyte mixture for protein stabilization
EP2535410A4 (en) 2010-02-12 2014-08-13 Ribomic Inc APTAMER FOR FGF2 AND USE THEREOF
JP6634554B2 (ja) * 2014-03-24 2020-01-22 株式会社リボミック Ｆｇｆ２に対するアプタマー及びその使用
JP2018124390A (ja) 2017-01-31 2018-08-09 株式会社沖データ 画像形成装置及び定着制御方法

Also Published As

Publication number Publication date
WO2020004607A1 (ja) 2020-01-02
EP3815715A1 (en) 2021-05-05
CA3105002A1 (en) 2020-01-02
BR112020026634A2 (pt) 2021-04-06
JPWO2020004607A1 (ja) 2021-07-15
EP3815715A4 (en) 2022-03-16
JP7340264B2 (ja) 2023-09-07
AU2019292134A1 (en) 2021-02-11
KR20210025083A (ko) 2021-03-08
IL279595A (en) 2021-03-01
CN112384246A (zh) 2021-02-19
SG11202012933QA (en) 2021-01-28
TW202012625A (zh) 2020-04-01
US20210269802A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MX2021009377A (es) Formulaciones de espuma y aparatos para su suministro.
MY185500A (en) Macrocylic pyridine derivatives
MY173573A (en) Pyridin-4-yl derivatives
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
TW201613592A (en) Glucose metabolism ameliorating agent
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX2020014124A (es) Preparacion de aptameros.
AU2017370226A1 (en) Pharmaceutical composition containing insulin-like growth factor-2 and use thereof
EA201691741A1 (ru) Фармацевтическая композиция
PH12019501785A1 (en) Intranasal composition comprising betahistine
MX2017011005A (es) Formulaciones estimulantes de liberacion tripulsos.
GEP20237486B (en) Formulations of copanlisib
MX2020008129A (es) Composicion farmaceutica que comprende un derivado acilado de un analogo de insulina humana y metodo de preparacion de la misma.
PH12019500024A1 (en) Pharmaceutical compositions
CA3081484A1 (en) Finished fibrous structures and methods of their use and preparation
MX2022001772A (es) Formulaciones de isotretinoina y usos y metodos de las mismas.
IN2014DN10134A (es)
MY195763A (en) A Herbicidal Composition and Process Thereof
PH12020551547A1 (en) Pharmaceutical preparation
WO2015126151A3 (ko) 신곡 추출물을 포함하는 상처 치료용 조성물
EA201690706A1 (ru) Пенообразующий препарат и устройство для доставки
WO2014031034A8 (ru) Фармацевтические композиции, содержащие ипидакрин и их применение для лечения нарушений потенции и других форм половой активности
PH12019501049A1 (en) Pharmaceutical composition containing palonosetron as active ingredient
UA92219U (ru) Лекарственное средство с метронидазолом для лечения дерматологических заболеваний